

INVITATION

FRIDAY JULY
05

LUNG GRAFT-VERSUS-HOST DISEASE (GVHD) MEETING

MANCHESTER, UNITED KINGDOM

This information is intended only for healthcare professionals in Europe.

PRELIMINARY AGENDA

09:00 – 09:15	Registration
09:15 – 09:30	Welcome
09:30 – 10:15	Increasing importance of managing late effects of HSCT: Lung GvHD
10:15 – 11:00	Continual Monitoring of BMT Patients lung Capacity and Early Detection of Lung GvHD
11:00 – 11:15	Coffee break
11:15 – 12:00	Early Intervention and Outcomes of treated Lung GvHD
12:00 – 12:30	Long term Strategy for Optimal Respiratory Care
12:30 – 12:40	Q&A
12:40 – 12:45	Meeting close
12:45 – 13:45	Lunch
13:45 – 16:00	Group Frame Work Meeting

To confirm your attendance please email Claire.evans@mnk.com

All speakers are subject to contract.

This is a commercial programme run by Therakos (UK) Ltd, a Mallinckrodt Company.

[Privacy policy](#) [Legal notice](#)

Learn more about Mallinckrodt Pharmaceuticals by visiting www.mallinckrodt.com
Mallinckrodt, the “M” brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company.
Other brands are trademarks of a Mallinckrodt company or their respective owners. © 2019 Mallinckrodt.

Item code: EU-1900036. Date of preparation: April 2019.

Although we have determined that we have a legitimate interest in using your data for marketing and sales purposes as per the terms of the current data protection legislation, you can opt-out by replying to this mail indicating “unsubscribe” in the email body. Our Privacy Notice provides additional information.